STOMP is a randomized, controlled, double-blind trial to evaluate the safety and effectiveness of Tpoxx for treating mpox. In ...

It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug ...

As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...

Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild ...

The STOMP study found tecovirimat safe but ineffective in reducing lesion resolution or pain in adults with mild to moderate ...

Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II ...

The only available antiviral treatment for mpox is called Tpoxx (tecovirimat). A study sponsored by the National Institute of ...

NIH study finds tecovirimat was safe but did not improve mpox resolution or pain: Bethesda, Maryland Thursday, December 12, 2024, 15:00 Hrs [IST] The antiviral drug tecovirimat di ...

Siga Technologies' antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among ...

Siga's financial stability is threatened by potential policy changes, while Emergent's favorable valuation metrics position ...

CIDRAP: Recombinant Pertussis Vaccine May Protect Teens For At Least 5 Years Researchers report that immunity against pertussis (whooping cough) was sustained 5 years after receipt of a ...